Clinical Trial Update: Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating response-adapted initial therapy for multiple myeloma using bortezomib/dexamethasone, with lenalidomide added for non-responders. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma (MM) | Phase 2 | Status: COMPLETED | Results posted: 2026-03-02